US20140322252A1 - Peptides for Treating Alzheimers's Disease and Related Conditions - Google Patents
Peptides for Treating Alzheimers's Disease and Related Conditions Download PDFInfo
- Publication number
- US20140322252A1 US20140322252A1 US14/263,560 US201414263560A US2014322252A1 US 20140322252 A1 US20140322252 A1 US 20140322252A1 US 201414263560 A US201414263560 A US 201414263560A US 2014322252 A1 US2014322252 A1 US 2014322252A1
- Authority
- US
- United States
- Prior art keywords
- thr
- ser
- seq
- peptide
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 57
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 25
- 102000004196 processed proteins & peptides Human genes 0.000 title description 31
- 210000004556 brain Anatomy 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000000626 neurodegenerative effect Effects 0.000 claims abstract description 10
- 208000000044 Amnesia Diseases 0.000 claims abstract description 5
- 231100000863 loss of memory Toxicity 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 230000007659 motor function Effects 0.000 claims abstract 3
- 208000014674 injury Diseases 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 5
- 208000032274 Encephalopathy Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 208000016192 Demyelinating disease Diseases 0.000 claims description 4
- 206010060860 Neurological symptom Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000032859 Synucleinopathies Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 1
- 230000003925 brain function Effects 0.000 claims 1
- AKWRNBWMGFUAMF-ZESMOPTKSA-N (2s)-n-[(2s)-1-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amin Chemical compound C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(N)=O)CC1=CC=C(O)C=C1 AKWRNBWMGFUAMF-ZESMOPTKSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 14
- 108010024116 RAP-103 Proteins 0.000 description 13
- 230000036515 potency Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 108010071384 Peptide T Proteins 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 10
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 9
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000035605 chemotaxis Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 7
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 7
- 102000009410 Chemokine receptor Human genes 0.000 description 7
- 108050000299 Chemokine receptor Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- KVPFYRAFNZKJSD-CPXLMRBJSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 KVPFYRAFNZKJSD-CPXLMRBJSA-N 0.000 description 5
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- 210000001642 activated microglia Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000028550 monocyte chemotaxis Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000010174 APPSwe Methods 0.000 description 3
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 3
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 241001517013 Calidris pugnax Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 210000001056 activated astrocyte Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 208000025698 brain inflammatory disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000002314 neuroinflammatory effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- IWHCAJPPWOMXNW-ZESMOPTKSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)pr Chemical compound C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-ZESMOPTKSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010083930 HIV Receptors Proteins 0.000 description 1
- 102000006481 HIV Receptors Human genes 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101150100944 Nos2 gene Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 102000046768 human CCL2 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- the present invention relates, broadly to the treatment or prevention of loss of brain neurons, loss of memory, dementia's, loss of motor or any other normal function due to neurodegeneration caused or associated with aging or brain inflammation, whether caused by injury, trauma, concussive blasts, sports via head contact, bacteria, viruses and/or other infective agents, opportunistic infections (which may be consequential to an immunodepressed state, for example resulting from cancer or therapy, particularly immunosuppressive antibodies or cytotoxic drug therapy or radiotherapy), autoimmunity or otherwise.
- FIG. 1 illustrates the activity of Peptide T analogs in chemotaxis of human monocytes.
- FIG. 2 illustrates chemotaxis of human monocytes for several all D pentapeptides.
- FIG. 3 illustrates that D-ala1-STTTNYT-NH2 (DAPTA/RAP-101) and all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) both inhibit CCR8 function.
- FIG. 4 illustrates cofilin-actin rod stress response is blocked by that all D-ASTTTNYT (SEQ ID NO:1).
- the invention relates to the prevention or treatment of neurodegenerative illnesses which may include Alzheimer's Disease, Huntington's Disease and the synucleinopathies such as Parkinson's Disease, or demyelinating diseases such as HTLV-1-associated myelopathy (HAM), multiple sclerosis (MS), amyotrophic lateral sclerosis and pathological neurological symptoms after injury or trauma, or viral and other encephalopathies which are associated with chronic immune activation that occurs as a result of dysregulated inflammation, some examples of which include cytokine, chemokine, and toll-receptor inflammatory pathways and activation of the microglia or astrocytes.
- the invention also relates to pharmaceutical compositions useful in such treatment and/or prevention and to certain orally active peptides per se.
- Inflammation clearly occurs in pathologically susceptible regions of the Alzheimer's disease (AD) brain. Neurodegeneration and neuroinflammation can result in changes of central nervous system (CNS) proteins (for example, amyloid-beta (A ⁇ ) peptide) or inflammatory mediators (acute-phase proteins and pro-inflammatory cytokines and chemokines) across the blood-brain-barrier (BBB).
- CNS central nervous system
- a ⁇ amyloid-beta
- inflammatory mediators acute-phase proteins and pro-inflammatory cytokines and chemokines
- BBB blood-brain-barrier
- MCP-1 monocyte chemoattractant protein-1
- RANTES and MIP-1 ⁇ chemokine ligands for the CCR5 receptor in response to non-fibrillar beta-amyloid protein.
- cytokines like TNF ⁇ and IL-10 promote reactive microglia and astrocytes causing a cascade of inflammatory factors and neurotoxic-mediators that are associated or co-existing in beta-amyloid plaques.
- the prototype compound DAPTA normalizes the activity of the enzyme Akt (or protein kinase B (PKB)), which is a multifunctional kinase implicated in a broad range of cellular functions, including survival, proliferation, gene expression, and migration of cells of most lineages.
- Akt signaling is newly understood to be involved in the regulation of acute and chronic inflammatory processes, and compounds that normalize, often by antagonizing excess activation of Akt isoforms, are promising drug targets for the modulation of inflammatory and autoimmune disorders including cancer and cardiovascular diseases as well as neurodegenerative illnesses.
- a proposed mechanism of action of DAPTA and the related subject compounds may include normalization of excessive inflammatory signaling via MAP kinase second messenger pathways.
- IL-1 ⁇ , IL-6, and tumor necrosis factor- ⁇ are known to be among the major cytokines up-regulated during CNS stress and injury.
- TNF ⁇ and other inflammatory cytokines exacerbates the activation of glial cells and promotes gliosis, inhibiting astrocytic glutamate uptake and inducing apoptosis, particularly in oligodendrocytes thereby contributing to damaging demyelination, as occurs in multiple sclerosis (MS).
- MS multiple sclerosis
- the ability to inhibit the action of TNF ⁇ and other inflammatory activators in the early phases of CNS illnesses may yield a salutary clinical outcome in diverse neurological diseases, including but not limited to multiple sclerosis and Alzheimers Disease.
- the compounds here described would also have significant patient benefit in the immune reconstitution inflammatory syndrome (IRIS)—a paradoxical deterioration of a preexisting condition, often an infection, related to the recovery of the immune system. If immune function improves rapidly following the commencement of a medical intervention or therapy, systemic or local inflammatory reactions may occur. This restoration of immunity may result in immunopathological reactions. In brain neurological symptoms can worsen and do not always spontaneously resolve, and may be life-threatening.
- IRIS immune reconstitution inflammatory syndrome
- DAPTA D-Ala 1 -Peptide T-NH2
- Rosi ⁇ Rosi ⁇ conducted a study of inflammatory effects in TLR4 stimulated (LPS-infused) rats treated with vehicle or the prototype peptide D-ala 1 -peptide T-NH2 (DAPTA) (0.01 mg/kg, s.c., for 14 days).
- DAPTA dramatically reduced the number of activated microglia and astrocytes, as compared with rats treated with vehicle.
- DAPTA treatment also reduced the number of immunoreactive cells expressing nuclear factor k binding protein (NfKb), a prominent component of the proinflammatory cytokine signaling pathway.
- NfKb nuclear factor k binding protein
- the prototype compound DAPTA thus has actions consistent with benefit in neuroinflammatory conditions, and those putative patient benefits therefore can be extended to other related peptides.
- NBM nucleus basalis
- DAPTA prevents nucleus basalis (NBM)-induced degenerative changes in the parietal neocortex of aged rats (33).
- NBM lesioned animals had: 1) a significant 17% decrease in overall cortical thickness, 2) significant decreases of 13-29% in the thickness of cortical layers II-IV, V, and VI, and 3) significant neuronal and glial cell loss in layer V.
- DAPTA treatment prevented or attenuated these lesion-induced decreases in cortical thickness and attenuated the accompanying loss of large neurons in layer V.
- DAPTA spares neuron loss after NBM lesion, via anti-inflammatory actions.
- An unexpected and non-obvious aspect of the present invention is the use of all-D amino-acid derivatives of the mostly L-amino-acid peptides so far described in the creation of novel orally active therapeutic peptides.
- Those results are unexpected and non-obvious in view of Pert, 1986 FIGS. 3 and 4 ⁇ Pert et al., 1986, #35987 ⁇ , which shows that that D for L substitutions in linear peptide ASTTTNYT (SEQ ID NO:1) (Peptide T) can cause great loss of potency.
- FIG. 1 An example is provided in FIG. 1 .
- DAPTA all-D-amino acid peptide analogs of DAPTA, such as all-D-ASTTTNYT-NH2 (RAP-107), all-D-Peptide ASTTTNYT (SEQ ID NO:1) (RAP-310), and the shorter pentapeptide All-D-TTNYT (SEQ ID NO:2) (RAP-103) that contains the core bioactive moiety of Peptide T ⁇ Ruff, Hallberg, Hill, Pert, 1987 ⁇ .
- RAPs all-D amino acid derivatives
- Peptide T all-L-ASTTTNYT (SEQ ID NO:1)
- MCP-1 CCL2
- Triplicate determinations were made and results are expressed as the mean plus or minus SEM.
- the experiment shown is a direct comparison among all RAPs.
- Statistical analysis was by unpaired t-test, with significance set at the p ⁇ 0.01 (*) level for difference from CCL2 only chemotaxis.
- FIG. 1 illustrates the activity of all-D compared to mostly L-form peptides of formula I. It is shown that three related peptides of general formula I, that have identical primary sequence or that share partial sequence, differing only in enantiomeric form, block CCL2 chemotaxis. The results are unexpected in view of ⁇ Brenneman; Ruff; Smith, ruff ⁇ which show that most L to D substitutions show reduced activity, and some cause complete loss of biopotency.
- RAP-101 is the monomeric form of DAPTA (U.S. Pat. No. 7,390,788) and shows greater potency.
- FIG. 2 We broadened ( FIG. 2 ) the list of efficacious all-D-peptides to include eight more unique examples (SSTYR (SEQ ID NO:3), TTSYT (SEQ ID NO:4), NTRYR (SEQ ID NO:5), IDNYT (SEQ ID NO:6), NTSYR (SEQ ID NO:7), IDNYT (SEQ ID NO:8), NTSYG (SEQ ID NO:9), ETWYS (SEQ ID NO:10)) of HIV envelope gp160 and more commonly gp120-V2 region, near the bridging sheet, at approximately amino-acid 185 in the V2-loop of the envelope protein, depending on HIV env isolate.
- SSTYR SEQ ID NO:3
- TTSYT SEQ ID NO:4
- NTRYR SEQ ID NO:5
- IDNYT SEQ ID NO:6
- NTSYR SEQ ID NO:7
- IDNYT SEQ ID NO:8
- NTSYG
- the synthetic derived all-D-pentapeptides with a tyrosine in the fourth position, and Ser, Thr, or Asp in the second position, that potently block CCR2/CCR5 chemotaxis are broad spectrum chemokine receptor antagonists useful as potential orally active peptide therapeutics.
- the difficulty of development of orally active peptides has greatly impeded their development as therapies.
- FIG. 2 we show that all-D-pentapeptides inhibit CCR2 (MCP-1) elicited chemotaxis of human monocytes.
- Purified human monocytes were treated with 20 ⁇ M of All-D-pentapeptides for 30 minutes prior to chemotaxis against human MCP-1 (0.6 nM) for 2 hours.
- the chemotactic index (ratio of migration for CCR2/buffer) for MCP-1 was 3-4.
- a representative experiment is shown comprising triplicate determinations and is presented as relative fluorescence units, Mean ⁇ SEM.
- the activity of All-D-pentapeptide TTNYT (SEQ ID NO:2) (RAP-103) to block MCP-1 human monocyte chemotaxis has been published, ⁇ Padi, 2012 ⁇ .
- the peptides share activity to block diverse chemokine receptors.
- DAPTA the prototype octapeptide (D-ala1-STTTNYT-NH2) blocks chemokine receptor 8 (CCR8) and the all-D-ASTTTNYT (SEQ ID NO:1) analog also blocks CCR8, with comparable potency.
- CCR8 chemokine receptor 8
- SEQ ID NO:1 the all-D-ASTTTNYT
- FIG. 3 we show D-ala 1 -STTTNYT-NH2 (DAPTA/RAP-101) and all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) both Inhibit CCR8 Function.
- RAP-101 and RAP-310 Both Inhibit CCL1 (1-309) mediated chemotaxis of human monocytes.
- Human monocytes isolated by Ficoll-Percoll gradient were cultured in complete growth medium (RPMI1640, supplemented with 10% FBS and 4 mM L-glutamine) in presence of M-CSF for 48 hours.
- M2 type macrophages Migration of type M2 monocyte derived macrophages toward CCL1 (I-309, 1 nM) were tested in presence or absence of D-ala 1 -STTTNYT-NH2 (DAPTA/RAP-101) and all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) at the indicated drug concentrations. The data represent the mean of triplicate determinations of a representative experiment.
- All-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) Blocks A ⁇ and TNF ⁇ induced cofilin rod formation, an early AD pathology.
- a ⁇ or Abeta denotes peptides of 36-43 amino acids that are crucially involved in AD as the main component of the amyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield A ⁇ . It is believed that certain misfolded oligomers (known as “seeds”) can induce other A ⁇ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The seeds or the resulting amyloid plaques are toxic to nerve cells.
- FIG. 4 all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) (the oral active form of Peptide T (ASTTTNYT (SEQ ID NO:1)), same sequence but all-L amino acids) to block A ⁇ , and TNF ⁇ formation of cofilin rods in cultured mouse hippocampal neurons, a very early event in neurodegeneration observed in AD patients. Formation of cofilin-actin rods precedes neuronal death.
- Peptide T or its analog DAPTA protects neurons from toxic effects of activated microglia such as secreted free radicals or cytokines, and so may be beneficial in neurodegenerative illnesses, like AD.
- activated microglia such as secreted free radicals or cytokines
- the Cofilin-Actin Rod Stress Response is blocked by RAP-310, EC50 about 0.1 pM.
- RAP-310 blocks A ⁇ dimer/trimer induced cofilin rods, so may protect to synaptic loss.
- TNF ⁇ also causes the cofilin-actin rod stress response and is comparably blocked by RAP-310 (not shown).
- the ability to substitute a D for an L amino acid and retain biopotency creates the possibility to make peptides orally deliverable drug compounds. Stability of peptides in biological fluids, such as plasma, or digestive enzymes has limited their utility as drugs.
- the ability to create all-D peptides that retain potency is an unexpected general method of creating oral peptides of General Formula I, and likely is useful for other peptides of five to twenty amino-acids, and perhaps larger, which may be stabilized to proteolysis, while retaining biopotency, so a therapeutic may be administered to people via oral dosing or otherwise enjoy benefit from longer bioavailability in the body necessitating fewer doses or reduced amount of active peptide.
- a pharmacokinetic study of all-D-TTNYT (SEQ ID NO:2) (RAP-103) following intravenous and oral administration was conducted at a target dose level of 1 mg/kg in the male Sprague Dawley rat.
- the concentration of RAP-103 in each plasma and brain sample was measured using a suitable LC-MS/MS assay.
- the assay used was a research grade assay (RGA-1) which was established by assessing the accuracy, precision and the linearity of the method. Plasma concentrations generated were used to evaluate the pharmacokinetic parameters of all-D-TTNYT (SEQ ID NO:2) (RAP-103).
- the dose formulation was administered intravenously to some animals as a slow bolus over ca 30 s via the tail vein and to a different group of animals orally via gastric gavage at a target dose volume of 1 mL/kg, to achieve a target dose level of 1 mg/kg.
- the dose volume administered was calculated according to the bodyweight of the animal on the day of dosing. The weight of administered dose was recorded. All dose administrations were well tolerated and no adverse effects from the treatments were observed. Results of the study show oral boavailibity of the all-D-peptide was achieved, results are in Table 1
- mice There is a marked inflammatory component in the mice and amyloid plaques and insoluble amyloid are detectable in mice at 9 months of age. Also while neuronal loss is not commonly observed in APPSw mice or many other mouse models of amyloid deposition thinning of the CA3 region of the hippocampus and the dentate gyrus is readily observed in APPSw/NOS2 ⁇ / ⁇ mice compared to APPSw mice.
- mice Both Transgenic (CVN) and wild-type (WT) mice were used: WT mice were treated orally (p.o.) with vehicle; while CVN mice treated p.o. with either vehicle or treated p.o. with RAP-310, 0.4 mg/kg. At the age of 4.5 to 5 months the mice were subjected to once-a-day oral vehicle or RAP-310. After 1 month of treatment, starting at the age of 6 months, the mice were subjected to radial arm water maze testing. At 9 months of age, the CVN RAP-310 orally treated mice made 50% less errors in block 5 and 30% less errors in sum scores for Day 1 compared to CVN vehicle treated mice.
- the peptides can be used in pharmaceutical compositions and compositions of matter for treating and preventing any disease or condition caused by an organism, compound or immune dysfunction that results in an inflammatory reaction of the immune system.
- the peptides or peptide formulations may be used alone or in combination with any other pharmaceutically active compound, such as an anti-infective agent, for example an antibiotic and/or antiviral agent and/or antifungal agent, or another pharmaceutically active compound, such as an antineoplastic agent.
- the peptides may be administered orally, bucally, parenterally, topically, rectally, vaginally, by intranasal inhalation spray, by intrapulmonary inhalation or in other ways.
- the peptides according to the invention may be formulated for topical use, for inhalation with spray or powder, for injection (for example subcutaneous, intramuscular, intravenous, intra-articular or intra-cisternal injection), for infusion or for oral administration, a preferred embodiment, and may be presented in unit dose form in ampoules or tablets or in multidose vials or other containers with an added preservative.
- compositions may take such forms as suspensions, solutions, or emulsions or gels in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
- the active ingredient may be in powder and/or lyophilised form for direct administration or for constitution with a suitable vehicle (e.g. sterile, pyrogen-free water, normal saline or dextrose or mannose) before use.
- a suitable vehicle e.g. sterile, pyrogen-free water, normal saline or dextrose or mannose
- the pharmaceutical compositions containing peptides(s) may also contain other active ingredients such as antimicrobial agents, or preservatives.
- compositions may contain from 0.001-99% (w/v or, preferably, w/w) of the active material.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A method of treating loss of memory or motor function due to brain neurodegenerative condition, such as Alzheimer's Disease and others, comprising the steps of:
-
- preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier,
- said D peptide further comprises the general structure: A-B-C-D-E-F-G-H
- in which:
- A is Ala, or absent,
- B is Ser, Thr or absent,
- C is Ser, Thr or absent,
- D is Ser, Thr, Asn, Glu, Arg, Ile, Leu,
- E is Ser, Thr, Asp, Asn,
- F is Thr, Ser, Asn, Arg, Gln, Lys, Trp,
- G is Tyr, and
- H is Thr, Ser, Arg, Gly,
- and wherein all amino acids are the D stereoisomeric configuration.
- said D peptide further comprises the general structure: A-B-C-D-E-F-G-H
- preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier,
The composition is administered to the patient in a therapeutically effective dose and acts to treat the condition in the patient.
Description
- This application claims the benefit of U.S. Provisional Application Ser. No. 61/816,565, filed Apr. 26, 2013.
- The present invention relates, broadly to the treatment or prevention of loss of brain neurons, loss of memory, dementia's, loss of motor or any other normal function due to neurodegeneration caused or associated with aging or brain inflammation, whether caused by injury, trauma, concussive blasts, sports via head contact, bacteria, viruses and/or other infective agents, opportunistic infections (which may be consequential to an immunodepressed state, for example resulting from cancer or therapy, particularly immunosuppressive antibodies or cytotoxic drug therapy or radiotherapy), autoimmunity or otherwise.
-
FIG. 1 illustrates the activity of Peptide T analogs in chemotaxis of human monocytes. -
FIG. 2 illustrates chemotaxis of human monocytes for several all D pentapeptides. -
FIG. 3 illustrates that D-ala1-STTTNYT-NH2 (DAPTA/RAP-101) and all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) both inhibit CCR8 function. -
FIG. 4 illustrates cofilin-actin rod stress response is blocked by that all D-ASTTTNYT (SEQ ID NO:1). - In particular embodiments, the invention relates to the prevention or treatment of neurodegenerative illnesses which may include Alzheimer's Disease, Huntington's Disease and the synucleinopathies such as Parkinson's Disease, or demyelinating diseases such as HTLV-1-associated myelopathy (HAM), multiple sclerosis (MS), amyotrophic lateral sclerosis and pathological neurological symptoms after injury or trauma, or viral and other encephalopathies which are associated with chronic immune activation that occurs as a result of dysregulated inflammation, some examples of which include cytokine, chemokine, and toll-receptor inflammatory pathways and activation of the microglia or astrocytes. The invention also relates to pharmaceutical compositions useful in such treatment and/or prevention and to certain orally active peptides per se.
- Inflammation clearly occurs in pathologically susceptible regions of the Alzheimer's disease (AD) brain. Neurodegeneration and neuroinflammation can result in changes of central nervous system (CNS) proteins (for example, amyloid-beta (Aβ) peptide) or inflammatory mediators (acute-phase proteins and pro-inflammatory cytokines and chemokines) across the blood-brain-barrier (BBB). These CNS-derived proteins and mediators induce both systemic and local in the brain immune reactions and/or recruit immune cells into the CNS. The cells responsible for the local inflammatory reaction in CNS are activated microglia and astrocytes. The hypothesis is that Aβ plaques and tangles stimulate a chronic inflammatory reaction. In addition to CNS resident cells, blood-derived cells can also be implicated in the inflammatory response and seem to both accumulate and activate in the AD brain due to the expression of chemokine receptors.
- Human monocytes and brain microglia express monocyte chemoattractant protein-1 (MCP-1), the chemokine ligand for the CCR2 receptor, and RANTES and MIP-1β, chemokine ligands for the CCR5 receptor in response to non-fibrillar beta-amyloid protein. These, and other actions, e.g, the release of cytokines like TNFα and IL-10 promote reactive microglia and astrocytes causing a cascade of inflammatory factors and neurotoxic-mediators that are associated or co-existing in beta-amyloid plaques.
- In order to overcome limitations of single-chemokine receptor targeted drugs, we have developed modified short peptide antagonists of multiple chemokine receptors CCR8/CCR5/CCR2/CX3CR1/CCR3 and TLR4, which are important innate immune targets in inflammatory conditions like AD. Because of the complexity and redundancies of innate defense pathways, new compounds that block multiple receptor targets, such as we have created, may prove to be better therapeutics.
- Further, the prototype compound DAPTA normalizes the activity of the enzyme Akt (or protein kinase B (PKB)), which is a multifunctional kinase implicated in a broad range of cellular functions, including survival, proliferation, gene expression, and migration of cells of most lineages. Akt signaling is newly understood to be involved in the regulation of acute and chronic inflammatory processes, and compounds that normalize, often by antagonizing excess activation of Akt isoforms, are promising drug targets for the modulation of inflammatory and autoimmune disorders including cancer and cardiovascular diseases as well as neurodegenerative illnesses. Thus a proposed mechanism of action of DAPTA and the related subject compounds may include normalization of excessive inflammatory signaling via MAP kinase second messenger pathways.
- IL-1β, IL-6, and tumor necrosis factor-α (TNFα) are known to be among the major cytokines up-regulated during CNS stress and injury. The release of TNFα and other inflammatory cytokines exacerbates the activation of glial cells and promotes gliosis, inhibiting astrocytic glutamate uptake and inducing apoptosis, particularly in oligodendrocytes thereby contributing to damaging demyelination, as occurs in multiple sclerosis (MS). The ability to inhibit the action of TNFα and other inflammatory activators in the early phases of CNS illnesses may yield a salutary clinical outcome in diverse neurological diseases, including but not limited to multiple sclerosis and Alzheimers Disease.
- In particular the compounds here described would also have significant patient benefit in the immune reconstitution inflammatory syndrome (IRIS)—a paradoxical deterioration of a preexisting condition, often an infection, related to the recovery of the immune system. If immune function improves rapidly following the commencement of a medical intervention or therapy, systemic or local inflammatory reactions may occur. This restoration of immunity may result in immunopathological reactions. In brain neurological symptoms can worsen and do not always spontaneously resolve, and may be life-threatening.
- In Vivo Model of Brain Inflammation Blocked by RAP101.
- Rosi {Rosi} conducted a study of inflammatory effects in TLR4 stimulated (LPS-infused) rats treated with vehicle or the prototype peptide D-ala1-peptide T-NH2 (DAPTA) (0.01 mg/kg, s.c., for 14 days). DAPTA dramatically reduced the number of activated microglia and astrocytes, as compared with rats treated with vehicle. DAPTA treatment also reduced the number of immunoreactive cells expressing nuclear factor k binding protein (NfKb), a prominent component of the proinflammatory cytokine signaling pathway. The prototype compound DAPTA thus has actions consistent with benefit in neuroinflammatory conditions, and those putative patient benefits therefore can be extended to other related peptides.
- In Vivo Model of Cortical Atrophy in Aged Rats is Blocked by D-Ala1-Peptide T-NH2 (DAPTA).
- Loss of the basal neurons, as occurs in aging, results in large reductions of cholinergic markers in cortex, a feature of AD clinical disease that has led to cholinergic therapies in AD. The loss of cortical neurons in aging can be experimentally induced by chemically induced lesions of nucleus basalis (NBM).
- DAPTA prevents nucleus basalis (NBM)-induced degenerative changes in the parietal neocortex of aged rats (33). Aged (20-21 months old) Sprague-Dawley rats were given bilateral neurotoxic lesions of the NBM, and injected daily with PT (1 mg, IP) or vehicle solution for 5 months. NBM lesioned animals had: 1) a significant 17% decrease in overall cortical thickness, 2) significant decreases of 13-29% in the thickness of cortical layers II-IV, V, and VI, and 3) significant neuronal and glial cell loss in layer V. DAPTA treatment prevented or attenuated these lesion-induced decreases in cortical thickness and attenuated the accompanying loss of large neurons in layer V. DAPTA spares neuron loss after NBM lesion, via anti-inflammatory actions.
- Although the animal experiments provide evidence of clinical utility, an unmet medical need is oral dosing of peptides as peptides rarely, if ever, can be administered orally without special measures to prevent proteolysis in the digestive tract. An unexpected and non-obvious aspect of the present invention is the use of all-D amino-acid derivatives of the mostly L-amino-acid peptides so far described in the creation of novel orally active therapeutic peptides. Those results are unexpected and non-obvious in view of Pert, 1986 FIGS. 3 and 4 {Pert et al., 1986, #35987}, which shows that that D for L substitutions in linear peptide ASTTTNYT (SEQ ID NO:1) (Peptide T) can cause great loss of potency.
- Having one D substitution, in the
specific position No 1, (the D-ala) retains potency. Making an additional D substitution, in the specific position No 8 (the D-Thr) results in loss of 99 to 99.9% of the activity. Thus it is shown that introduction of L to D substitutions cannot be made in a general fashion, and that these modifications can, and typically do, destroy biopotency by disrupting the peptide structure required for receptor potency. - This point is further made in Brenneman {Brenneman, 1988}, with specific reference to the peptide TTNYT (SEQ ID NO:2). See
FIG. 2 and Table 1. Upon making the L to D substitution in position 4 (Tyr), the peptide completely loses activity. This directly contradicts Andersen, U.S. Pat. No. 6,265,374 because each of the amino-acids CAN NOT be in the D-form and retain biopotency. The objection stands as Andersen provides no evidence that each amino-acid can be in a D-form. - A detailed study of the peptide TTNYT (SEQ ID NO:2) and L to D substitutions was published in Smith, 1988 {Smith, 1988}. Refer to
FIG. 3 . Introduction of single L to D substitutions in eachposition 1, 2, 3, 4, results in loss of potency, and all of the D form substitutions are substantially less active (50×) to completely inactive. - As such the use of D-substitutions by Andersen in “each” position has not been reduced to practice. The data shows that in no instance does a D for L amino-acid substitution achieve comparable potency to the all-L form, rather D substitutions result in loss of activity, sometimes complete loss of biopotency in a position dependent fashion. In contrast to the repeated findings of numerous authors (op. cit. above) we discovered, while seeking to construct an inactive version of linear peptides ASTTTNYT (SEQ ID NO:1) (“Peptide T”, {Pert et al., 1986, #35987}) or TTNYT (SEQ ID NO:2) by converting them to all-D-amino acids, an unexpected retention of biopotency to block chemokine receptors.
- An example is provided in
FIG. 1 . We synthesized three all-D-amino acid peptide analogs of DAPTA, such as all-D-ASTTTNYT-NH2 (RAP-107), all-D-Peptide ASTTTNYT (SEQ ID NO:1) (RAP-310), and the shorter pentapeptide All-D-TTNYT (SEQ ID NO:2) (RAP-103) that contains the core bioactive moiety of Peptide T {Ruff, Hallberg, Hill, Pert, 1987}. - The results show that all three “all-D” peptides, comprised of all D, no L, amino acids retained nearly full potency. As expected DAPTA, with 7 of 8 amino-acids as L form, was most potent and the other all-D amino-acid peptides were some 2 to 35-fold reduced in potency. The potency reductions will not affect clinical usefulness as all of the compounds are active at sub-nM and pM concentrations to antagonize chemokine receptors.
- Legend: The effect of all-D amino acid derivatives (“RAPs”, generic names) of Peptide T (all-L-ASTTTNYT (SEQ ID NO:1)) (Pert, 1986), the V2 derived antagonist of CCR5/CCR2 mediated HIV infection and inflammation, to block CCL2 (MCP-1) chemotaxis was studied. Triplicate determinations were made and results are expressed as the mean plus or minus SEM. The experiment shown is a direct comparison among all RAPs. Statistical analysis was by unpaired t-test, with significance set at the p<0.01 (*) level for difference from CCL2 only chemotaxis.
- Converting peptides of general formula I (ASTTTNYT (SEQ ID NO:1)) to all-D-amino acids retain similar receptor targets, and similar receptor potencies to block innate immune responses.
FIG. 1 illustrates the activity of all-D compared to mostly L-form peptides of formula I. It is shown that three related peptides of general formula I, that have identical primary sequence or that share partial sequence, differing only in enantiomeric form, block CCL2 chemotaxis. The results are unexpected in view of {Brenneman; Ruff; Smith, ruff} which show that most L to D substitutions show reduced activity, and some cause complete loss of biopotency. The tyrosine moiety is particularly sensitive and the peptides are not active in L-form with a D-tyrosine. RAP-101 is the monomeric form of DAPTA (U.S. Pat. No. 7,390,788) and shows greater potency. - We broadened (
FIG. 2 ) the list of efficacious all-D-peptides to include eight more unique examples (SSTYR (SEQ ID NO:3), TTSYT (SEQ ID NO:4), NTRYR (SEQ ID NO:5), IDNYT (SEQ ID NO:6), NTSYR (SEQ ID NO:7), IDNYT (SEQ ID NO:8), NTSYG (SEQ ID NO:9), ETWYS (SEQ ID NO:10)) of HIV envelope gp160 and more commonly gp120-V2 region, near the bridging sheet, at approximately amino-acid 185 in the V2-loop of the envelope protein, depending on HIV env isolate. The synthetic derived all-D-pentapeptides with a tyrosine in the fourth position, and Ser, Thr, or Asp in the second position, that potently block CCR2/CCR5 chemotaxis are broad spectrum chemokine receptor antagonists useful as potential orally active peptide therapeutics. The difficulty of development of orally active peptides has greatly impeded their development as therapies. Here we suggest a general method to stabilize peptides to proteolytic degradation that preserves biopotency, either as an agonist or as an antagonist of cell surface receptors. - In
FIG. 2 we show that all-D-pentapeptides inhibit CCR2 (MCP-1) elicited chemotaxis of human monocytes. Purified human monocytes were treated with 20 μM of All-D-pentapeptides for 30 minutes prior to chemotaxis against human MCP-1 (0.6 nM) for 2 hours. The chemotactic index (ratio of migration for CCR2/buffer) for MCP-1 was 3-4. A representative experiment is shown comprising triplicate determinations and is presented as relative fluorescence units, Mean±SEM. The activity of All-D-pentapeptide TTNYT (SEQ ID NO:2) (RAP-103) to block MCP-1 human monocyte chemotaxis has been published, {Padi, 2012}. - The peptides share activity to block diverse chemokine receptors. Thus we show that DAPTA, the prototype octapeptide (D-ala1-STTTNYT-NH2) blocks chemokine receptor 8 (CCR8) and the all-D-ASTTTNYT (SEQ ID NO:1) analog also blocks CCR8, with comparable potency. Thus again, with a different receptor target, the all-D peptide performs very similarly to its mostly L-amino acid prototype first described in Pert, 1986. See
FIG. 3 . - In
FIG. 3 we show D-ala1-STTTNYT-NH2 (DAPTA/RAP-101) and all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) both Inhibit CCR8 Function. RAP-101 and RAP-310 Both Inhibit CCL1 (1-309) mediated chemotaxis of human monocytes. Human monocytes isolated by Ficoll-Percoll gradient were cultured in complete growth medium (RPMI1640, supplemented with 10% FBS and 4 mM L-glutamine) in presence of M-CSF for 48 hours. Resting monocytes, as freshly isolated, were not responsive to CCL1, which required maturation with M-CSF for 48 hrs to up-regulate expression of CCR8, so-called “M2” type macrophages. Migration of type M2 monocyte derived macrophages toward CCL1 (I-309, 1 nM) were tested in presence or absence of D-ala1-STTTNYT-NH2 (DAPTA/RAP-101) and all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) at the indicated drug concentrations. The data represent the mean of triplicate determinations of a representative experiment. - All-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) Blocks Aβ and TNFα induced cofilin rod formation, an early AD pathology. Aβ or Abeta, denotes peptides of 36-43 amino acids that are crucially involved in AD as the main component of the amyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. It is believed that certain misfolded oligomers (known as “seeds”) can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The seeds or the resulting amyloid plaques are toxic to nerve cells.
- We tested (
FIG. 4 ) all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) (the oral active form of Peptide T (ASTTTNYT (SEQ ID NO:1)), same sequence but all-L amino acids) to block Aβ, and TNFα formation of cofilin rods in cultured mouse hippocampal neurons, a very early event in neurodegeneration observed in AD patients. Formation of cofilin-actin rods precedes neuronal death. Our studies show that Peptide T or its analog DAPTA protects neurons from toxic effects of activated microglia such as secreted free radicals or cytokines, and so may be beneficial in neurodegenerative illnesses, like AD. InFIG. 4 , the Cofilin-Actin Rod Stress Response is blocked by RAP-310, EC50 about 0.1 pM. Thus RAP-310 blocks Aβ dimer/trimer induced cofilin rods, so may protect to synaptic loss. TNFα also causes the cofilin-actin rod stress response and is comparably blocked by RAP-310 (not shown). - The ability to substitute a D for an L amino acid and retain biopotency creates the possibility to make peptides orally deliverable drug compounds. Stability of peptides in biological fluids, such as plasma, or digestive enzymes has limited their utility as drugs. The ability to create all-D peptides that retain potency is an unexpected general method of creating oral peptides of General Formula I, and likely is useful for other peptides of five to twenty amino-acids, and perhaps larger, which may be stabilized to proteolysis, while retaining biopotency, so a therapeutic may be administered to people via oral dosing or otherwise enjoy benefit from longer bioavailability in the body necessitating fewer doses or reduced amount of active peptide.
- A pharmacokinetic study of all-D-TTNYT (SEQ ID NO:2) (RAP-103) following intravenous and oral administration was conducted at a target dose level of 1 mg/kg in the male Sprague Dawley rat. The concentration of RAP-103 in each plasma and brain sample was measured using a suitable LC-MS/MS assay. The assay used was a research grade assay (RGA-1) which was established by assessing the accuracy, precision and the linearity of the method. Plasma concentrations generated were used to evaluate the pharmacokinetic parameters of all-D-TTNYT (SEQ ID NO:2) (RAP-103).
- The dose formulation was administered intravenously to some animals as a slow bolus over ca 30 s via the tail vein and to a different group of animals orally via gastric gavage at a target dose volume of 1 mL/kg, to achieve a target dose level of 1 mg/kg. The dose volume administered was calculated according to the bodyweight of the animal on the day of dosing. The weight of administered dose was recorded. All dose administrations were well tolerated and no adverse effects from the treatments were observed. Results of the study show oral boavailibity of the all-D-peptide was achieved, results are in Table 1
-
TABLE 1 CONCENTRATION OF ALL-D-TTNYT (RAP-103) IN MALE RAT PLASMA FOLLOWING INTRAVENOUS ADMINISTRATION AT A TARGET DOSE LEVEL OF 1 MG/KG. RESULTS EXPRESSED AS NG/ML Nominal Time Animal Number (h) 007 M 008 M 009 M 010 M 011 M 012 M 013 M 014 M 015 M 016 M 017 M 0.083 3050 2490 — — — — — — — — — 0.167 — — 2400 2500 — — — — — — — 0.25 — — — — 2050 2270 1860 — — — — 0.5 — — — — — — — 558 561 — — 1 — — — — — — — — — 405 433 - The results show that as quickly as can be determined, 5 minutes (0.083 hrs) after dosing, all-D-TTNYT (SEQ ID NO:2) (RAP-103) is detected in plasma, and continues to be detected at 1 hr. Peak levels occur at 10-15 minutes.
- The biological relevance is shown in the publication by Padi et al., {Padi} that shows oral administration of RAP-103 (0.05-1 mg/kg) for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia after partial ligation of the sciatic nerve in rats. Administered from days 8 to 12, RAP-103 (0.2-1 mg/kg) reverses already established hypersensitivity. RAP-103 relieves behavioral hypersensitivity through either or both CCR2 and CCR5 blockade. Moreover, RAP-103 is able to reduce spinal microglial activation and monocyte infiltration, and to inhibit inflammatory responses evoked by peripheral nerve injury that cause chronic pain. The findings suggest that targeting CCR2/CCR5 should provide greater efficacy than targeting CCR2 or CCR5 alone, and that the dual CCR2/CCR5 antagonist RAP-103 has the potential for broad clinical use in neuropathic pain treatment.
- We tested yet a further all-D-amino acid modified peptide for oral bioavailability and protection to memory losses in an animal AD model. Thus all-D-ASTTTNYT (SEQ ID NO:1) (RAP-310) (the oral active form of Peptide T (ASTTTNYT (SEQ ID NO:1)) on cognitive performance in the Morris Radial Arm Water Maze (RAWM) in the Alzheimer's disease (AD) transgenic mouse (“CVN” model; APPSwDI/NOS2−/−.) {Colton, 2008} was studied. CVN mice (APP with Swedish, Dutch and Iowa mutations crossed with NOS2 knockout) exhibit memory and learning deficits as well as biochemical hallmarks of AD during aging. There is a marked inflammatory component in the mice and amyloid plaques and insoluble amyloid are detectable in mice at 9 months of age. Also while neuronal loss is not commonly observed in APPSw mice or many other mouse models of amyloid deposition thinning of the CA3 region of the hippocampus and the dentate gyrus is readily observed in APPSw/NOS2−/− mice compared to APPSw mice.
- Both Transgenic (CVN) and wild-type (WT) mice were used: WT mice were treated orally (p.o.) with vehicle; while CVN mice treated p.o. with either vehicle or treated p.o. with RAP-310, 0.4 mg/kg. At the age of 4.5 to 5 months the mice were subjected to once-a-day oral vehicle or RAP-310. After 1 month of treatment, starting at the age of 6 months, the mice were subjected to radial arm water maze testing. At 9 months of age, the CVN RAP-310 orally treated mice made 50% less errors in
block 5 and 30% less errors in sum scores forDay 1 compared to CVN vehicle treated mice. These results show that daily treatment with oral RAP-310 (0.4 mg/kg) starting at age 4.5-5 months of age has beneficial effects on RAWM performance at age 9 months in APPSwDI/NOS2−/− transgenic mouse model of Alzheimer's disease. - Treatment Uses in Diseases with Underlying Inflammation
- The peptides can be used in pharmaceutical compositions and compositions of matter for treating and preventing any disease or condition caused by an organism, compound or immune dysfunction that results in an inflammatory reaction of the immune system. The peptides or peptide formulations may be used alone or in combination with any other pharmaceutically active compound, such as an anti-infective agent, for example an antibiotic and/or antiviral agent and/or antifungal agent, or another pharmaceutically active compound, such as an antineoplastic agent.
- The peptides may be administered orally, bucally, parenterally, topically, rectally, vaginally, by intranasal inhalation spray, by intrapulmonary inhalation or in other ways. In particular, the peptides according to the invention may be formulated for topical use, for inhalation with spray or powder, for injection (for example subcutaneous, intramuscular, intravenous, intra-articular or intra-cisternal injection), for infusion or for oral administration, a preferred embodiment, and may be presented in unit dose form in ampoules or tablets or in multidose vials or other containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions or gels in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder and/or lyophilised form for direct administration or for constitution with a suitable vehicle (e.g. sterile, pyrogen-free water, normal saline or dextrose or mannose) before use. The pharmaceutical compositions containing peptides(s) may also contain other active ingredients such as antimicrobial agents, or preservatives.
- The compositions may contain from 0.001-99% (w/v or, preferably, w/w) of the active material.
-
- Brenneman, D. E., J. M. Buzy, M. R. Ruff, and C. B. Pert. 1988. Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus. Drug Devel Res. 15:361-369
- Colton, C. A., D. M. Wilcock, D. A. Wink, J. Davis, W. E. Van Nostrand, and M. P. Vitek. 2008. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis. 15:571-587
- Padi, S. S., X. Q. Shi, Y. Q. Zhao, M. R. Ruff, N. Baichoo, C. B. Pert, and J. Zhang. 2012. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain. 153:95-106. doi:10.1016/j.pain.2011.09.022.
- Pert, C. B., J. M. Hill, M. R. Ruff, R. M. Berman, W. G. Robey, L. O. Arthur, F. W. Ruscetti, and W. L. Farrar. 1986. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci USA. 83:9254-928.
- Rosi, S., C. B. Pert, M. R. Ruff, K. Gann-Gramling, and G. L. Wenk. 2005. Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. Neuroscience. 134:671-676
- Ruff, M. R., P. L. Hallberg, J. M. Hill, and C. B. Pert. 1987a. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment [letter]. Lancet. 2:751
- Ruff, M. R., B. M. Martin, E. I. Ginns, W. L. Farrar, and C. B. Pert. 1987b. CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide. FEBS Lett. 211:17-22
- Smith, C. C., P. L. Hallberg, P. Sacerdote, P. Williams, E. Sternberg, B. Martin, C. Pert, and M. R. Ruff. 1988. Tritiated D-ala1-peptide T binding: A pharmacologic basis for the design of drugs which inhibit HIV receptor binding. Drug Devel Res. 15:371-379
- Socci, D. J., C. B. Pert, M. R. Ruff, and G. W. Arendash. 1996. Peptide T prevents NBM lesion-induced cortical atrophy in aged rats. Peptides. 17:831-837
Claims (11)
1. A method of treating brain neurodegenerative condition in a patient comprising the steps of:
preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier,
said D peptide further comprises the general structure: A-B-C-D-E-F-G-H in which:
A is Ala, or absent,
B is Ser, Thr or absent,
C is Ser, Thr or absent,
D is Ser, Thr, Asn, Glu, Arg, Ile, Leu,
E is Ser, Thr, Asp, Asn,
F is Thr, Ser, Asn, Arg, Gln, Lys, Trp,
G is Tyr, and
H is Thr, Ser, Arg, Gly,
and wherein all amino acids are the D stereoisomeric configuration, and administering said composition to the patient in a therapeutically effective dose,
wherein said composition acts to treat the brain neurodegenerative condition in the patient.
2. The method as defined in claim 1 wherein the brain neurodegenerative condition further comprises loss of memory or motor function.
3. The method as defined in claim 1 wherein said condition is selected from the group consisting of:
Alzheimers's Disease, Huntington's Disease, synucleinopathy, Parkinson's Disease, demyelinating disease, HTLV-1-associated myelopathy (HAM), multiple sclerosis (MS), amyotrophic lateral sclerosis, pathological neurological symptoms after injury or trauma, encephalopathy and viral encephalopathy.
4. The method as defined in claim 1 wherein said administering said composition to the patient is selected from the group consisting of administrating: orally, bucally, parenterally, topically, rectally, vaginally, by intranasal inhalation spray, by intrapulmonary inhalation.
5. The method as defined in claim 1 further comprising,
said D peptide is at most twenty (20) D amino acid residues in length and contains five contiguous D amino acid residues that have a sequence selected from the group consisting of:
6. The method as defined in claim 5 further comprising,
said D peptide derivative is at most twelve (12) D amino acid residues in length.
7. The method as defined in claim 5 further comprising,
said D peptide derivative is at most eight (8) D amino acid residues in length.
8. The method as defined in claim 5 further comprising,
said D peptide is five (5) D amino acid residues in length.
9. A method of treating brain neurodegenerative condition in a patient comprising the steps of:
treating loss of brain function in a patient comprising the steps of:
preparing a composition comprising a peptide analog and a pharmaceutically acceptable carrier,
said peptide analog is [D-Ala1]-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH2 SEQ ID NO:1 in which the first amino acid is a D stereoisomer and the remaining amino acids are L stereoisomers and the last amino acid has an amide cap, and
administering said peptide analog to the patient in a therapeutically effective dose,
wherein said composition acts to treat the brain neurodegenerative condition in the patient.
10. The method as defined in claim 9 wherein the brain neurodegenerative condition further comprises loss of memory or motor function.
11. The method as defined in claim 9 wherein said condition is selected from the group consisting of: Alzheimer's Disease, Huntington's Disease, synucleinopathy, Parkinson's Disease, demyelinating disease, HTLV-1-associated myelopathy (HAM), multiple sclerosis (MS), amyotrophic lateral sclerosis, pathological neurological symptoms after injury or trauma, encephalopathy and viral encephalopathy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/263,560 US20140322252A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for Treating Alzheimers's Disease and Related Conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361816565P | 2013-04-26 | 2013-04-26 | |
US14/263,560 US20140322252A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for Treating Alzheimers's Disease and Related Conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140322252A1 true US20140322252A1 (en) | 2014-10-30 |
Family
ID=51789424
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/263,519 Abandoned US20140322251A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions |
US14/263,560 Abandoned US20140322252A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for Treating Alzheimers's Disease and Related Conditions |
US14/263,493 Abandoned US20140322250A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for the Treatment of Multiple Sclerosis and Related Diseases |
US14/263,347 Active US10501494B2 (en) | 2013-04-26 | 2014-04-28 | Uses of peptides to treat brain injury and disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/263,519 Abandoned US20140322251A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/263,493 Abandoned US20140322250A1 (en) | 2013-04-26 | 2014-04-28 | Peptides for the Treatment of Multiple Sclerosis and Related Diseases |
US14/263,347 Active US10501494B2 (en) | 2013-04-26 | 2014-04-28 | Uses of peptides to treat brain injury and disease |
Country Status (1)
Country | Link |
---|---|
US (4) | US20140322251A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112703008A (en) * | 2017-07-18 | 2021-04-23 | 创新生物肽有限公司 | Oral anti-inflammatory peptides for the treatment of epilepsy, seizures and CNS disorders |
US20210244788A1 (en) * | 2020-02-06 | 2021-08-12 | Creative Bio-Peptides Inc. | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines |
EP4039264A1 (en) * | 2021-02-08 | 2022-08-10 | Creative Bio-Peptides Inc. | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines |
US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2914515C (en) | 2013-07-02 | 2018-12-11 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-i |
MA40985A (en) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | MULTIPLE SCLEROSIS TREATMENT METHODS |
US10624944B2 (en) * | 2017-06-19 | 2020-04-21 | Creative Bio-Peptides Inc. | Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH) |
US10624945B2 (en) * | 2017-10-31 | 2020-04-21 | Creative Bio-Peptides Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
WO2022261321A1 (en) * | 2021-06-09 | 2022-12-15 | Creative Bio-Peptides, Inc. | Compositions and methods for treating persistent postsurgical pain |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020102A1 (en) * | 1992-03-27 | 1993-10-14 | Peptide Technology Limited | Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis |
US5447915A (en) * | 1990-02-28 | 1995-09-05 | President And Fellows Of Harvard College | Terminally blocked antiviral peptides |
US5545719A (en) * | 1990-05-01 | 1996-08-13 | Neuromedica, Inc. | Nerve growth peptides |
US5756449A (en) * | 1992-05-14 | 1998-05-26 | Peptide Technology Limited | Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
US5776892A (en) * | 1990-12-21 | 1998-07-07 | Curative Health Services, Inc. | Anti-inflammatory peptides |
US6713445B1 (en) * | 1998-04-06 | 2004-03-30 | Advanced Immuni T, Inc. | Peptides for treatment of HIV infection |
US20060292167A1 (en) * | 2005-06-23 | 2006-12-28 | Michael Ruff | Therapeutic Peptides and Vaccines |
US20110245180A1 (en) * | 2010-02-09 | 2011-10-06 | Rapid Pharmaceuticals, Ag | Modified Peptide that reduces pain in peripheral neuropathy |
US8178497B2 (en) * | 2007-11-14 | 2012-05-15 | Rapid Pharmaceuticals Ag | Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5276016A (en) | 1986-06-03 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Small peptides which inhibit binding to T-4 receptors and act as immunogens |
US6242564B1 (en) | 1986-06-03 | 2001-06-05 | Candace B. Pert | Treatment of tropical spastic paresis with peptide T |
US5063206A (en) | 1988-12-16 | 1991-11-05 | The United States Of Americas As Represented By The Department Of Health And Human Services | Compositions having use as treatment of neuropsychiatric deficits |
US5739109A (en) | 1988-12-16 | 1998-04-14 | Advanced Immunit Inc. | Method of treating neuroinflammatory degenerative diseases |
US6011014A (en) | 1992-03-27 | 2000-01-04 | Advanced Immunit, Inc. | Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis |
US5534495A (en) | 1993-05-25 | 1996-07-09 | Advanced Peptides And Biotechnology Sciences | Treatment of non-HIV neuropathic pain syndromes |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US8916517B2 (en) * | 2009-11-02 | 2014-12-23 | The Administrators Of The Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
-
2014
- 2014-04-28 US US14/263,519 patent/US20140322251A1/en not_active Abandoned
- 2014-04-28 US US14/263,560 patent/US20140322252A1/en not_active Abandoned
- 2014-04-28 US US14/263,493 patent/US20140322250A1/en not_active Abandoned
- 2014-04-28 US US14/263,347 patent/US10501494B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
US5447915A (en) * | 1990-02-28 | 1995-09-05 | President And Fellows Of Harvard College | Terminally blocked antiviral peptides |
US5545719A (en) * | 1990-05-01 | 1996-08-13 | Neuromedica, Inc. | Nerve growth peptides |
US5776892A (en) * | 1990-12-21 | 1998-07-07 | Curative Health Services, Inc. | Anti-inflammatory peptides |
WO1993020102A1 (en) * | 1992-03-27 | 1993-10-14 | Peptide Technology Limited | Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis |
US5756449A (en) * | 1992-05-14 | 1998-05-26 | Peptide Technology Limited | Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease |
US6713445B1 (en) * | 1998-04-06 | 2004-03-30 | Advanced Immuni T, Inc. | Peptides for treatment of HIV infection |
US20060292167A1 (en) * | 2005-06-23 | 2006-12-28 | Michael Ruff | Therapeutic Peptides and Vaccines |
US7700115B2 (en) * | 2005-06-23 | 2010-04-20 | Rapid Pharmaceuticals Ag | Therapeutic peptides and vaccines |
US20100184705A1 (en) * | 2005-06-23 | 2010-07-22 | Michael Ruff | Therapeutic Peptides and Vaccines |
US8178497B2 (en) * | 2007-11-14 | 2012-05-15 | Rapid Pharmaceuticals Ag | Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA |
US20110245180A1 (en) * | 2010-02-09 | 2011-10-06 | Rapid Pharmaceuticals, Ag | Modified Peptide that reduces pain in peripheral neuropathy |
Non-Patent Citations (1)
Title |
---|
the fact sheet of MS retrieved from the website http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/?report=printable on 1/12/15. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112703008A (en) * | 2017-07-18 | 2021-04-23 | 创新生物肽有限公司 | Oral anti-inflammatory peptides for the treatment of epilepsy, seizures and CNS disorders |
US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
US20210244788A1 (en) * | 2020-02-06 | 2021-08-12 | Creative Bio-Peptides Inc. | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines |
EP4039264A1 (en) * | 2021-02-08 | 2022-08-10 | Creative Bio-Peptides Inc. | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines |
Also Published As
Publication number | Publication date |
---|---|
US20140322251A1 (en) | 2014-10-30 |
US20140323393A1 (en) | 2014-10-30 |
US20140322250A1 (en) | 2014-10-30 |
US10501494B2 (en) | 2019-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140322252A1 (en) | Peptides for Treating Alzheimers's Disease and Related Conditions | |
KR20080033331A (en) | Treatment of tumors | |
CN108472329B (en) | Use of polypeptides to stimulate the immune system | |
JPH10509428A (en) | Neurotrophic peptide of activity-dependent neurotrophic factor | |
KR20100014596A (en) | Template-fixed peptidomimetics | |
KR100831633B1 (en) | Peptides that antagonize fpr class receptor mediated signaling | |
EP1940436B1 (en) | Methods for treating immune mediated neurological diseases | |
US20240238363A1 (en) | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines | |
CN101921314B (en) | Brain-targeting neurotrophic factor fusion polypeptide for preventing and treating Alzheimer's disease and preparation method | |
US9623084B2 (en) | Methods for treating multiple sclerosis | |
US6727260B2 (en) | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | |
EP3143036B1 (en) | Par-1 based therapeutic conjugates and uses thereof | |
JP6708646B2 (en) | Neurodegenerative disorder | |
US5534495A (en) | Treatment of non-HIV neuropathic pain syndromes | |
WO2016033774A1 (en) | Β-lamella blocking peptide used for preventing and/or treating alzheimer's disease | |
EP4248985A1 (en) | Peptides for the treatment of retinitis pigmentosa | |
JPH09510688A (en) | Peptide inhibitor of CXC intercrine molecule | |
WO2012015910A2 (en) | Use of adnf polypeptides for treating neurodegenerative diseases | |
JP2012201621A (en) | Peptide compound inhibiting trka and use thereof | |
EP4039264A1 (en) | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines | |
US20150376235A1 (en) | Peptides for the Treatment of Immune Reconstitution Inflammatory Syndrome (IRIS) and Related Diseases | |
JP2004531480A (en) | Tripeptide derivatives for the treatment of neurodegenerative diseases | |
CN109476702B (en) | Peptides and uses thereof | |
WO2014075137A1 (en) | Peptides incorporating amino-substituted lactams for treatment of retinopathy | |
KR101943852B1 (en) | A novel peptide and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CREATIVE BIO-PEPTIDES INC, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RUFF, MICHAEL R;REEL/FRAME:047910/0114 Effective date: 20180516 |